Collaboration with NCI’s Cancer Therapy Evaluation Program (CTEP) will evaluate IMNN-001
in new indications and combination regimens

IMUNON retains ownership of its background intellectual property with an opportunity to expand its IP through this collaboration

LAWRENCEVILLE, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) — IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health. Under the CRADA, IMUNON and the NCI’s Cancer Therapy Evaluation Program (CTEP) who assumes regulatory sponsorship will support further clinical and non-clinical development of IMNN-001, the Company’s DNA-based IL-12 immunotherapy, under the NCI Experimental Therapeutics (NExT) Program managed by CTEP. IMNN-001 is the first gene-based immunotherapy selected by NCI/CTEP for partnered clinical development under a CRADA.

Under the agreement, NCI investigators will evaluate IMNN-001 in new solid tumor indications and combination regimens, building on clinical data from the Company’s ongoing ovarian cancer program. IMUNON will retain ownership of its background intellectual property and will retain ownership of new intellectual property solely generated by IMUNON under the collaboration, including the right to use the data generated under the collaboration for the research and development of IMNN-001. For IMUNON, the collaboration provides an opportunity to leverage the NCI resources for generating additional clinical data for IMNN-001 in new indications.

“We believe our CRADA with NCI’s CTEP will explore the broad potential of IMNN-001 and our TheraPlas® platform,” said Stacy Lindborg, Ph.D., President and Chief Executive Officer of IMUNON. “This partnership allows us to efficiently explore new indications and combinations through the expertise of CTEP and the National Clinical Trials Network (NCTN) utilizing the centralized clinical trial infrastructure funded by NCI, while keeping our team fully focused on advancing our pivotal Phase 3 OVATION 3 study in frontline ovarian cancer as rapidly as possible.”

“The mechanistic rationale for IL-12 as a multipotent immune activator extends well beyond ovarian cancer, and this collaboration gives us a capital-efficient way to initiate additional clinical trials for IMNN-001 across diverse solid tumor types and indications,” said Douglas V. Faller, M.D., Ph.D., Executive Vice President and Chief Medical Officer of IMUNON.

IMNN-001 is currently being evaluated in IMUNON’s pivotal Phase 3 OVATION 3 trial in frontline advanced ovarian cancer, following encouraging results from the completed Phase 2 OVATION 2 study, in which IMNN-001 was associated with a 14.7-month increase in median overall survival compared to chemotherapy alone (45.1 vs. 30.4 months).

About IMNN-001 Immunotherapy

Designed using IMUNON’s proprietary TheraPlas® platform technology, IMNN-001 is an IL-12 DNA plasmid vector encased in a nanoparticle delivery system that enables cell transfection followed by persistent, local secretion of the IL-12 protein. IL-12 is one of the most active cytokines for the induction of potent anticancer immunity, acting through the induction of T-lymphocyte and natural killer cell proliferation. IMUNON previously reported positive results from the completed Phase 2 OVATION 2 Study, which assessed IMNN-001 plus neoadjuvant and adjuvant chemotherapy compared to standard-of-care chemotherapy alone in 112 patients with newly diagnosed advanced ovarian cancer. IMNN-001 is now being evaluated in the Company’s pivotal Phase 3 OVATION 3 trial, enrolling patients with newly diagnosed advanced ovarian cancer at clinical sites across the U.S.

About IMUNON

IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the gene delivery of viral antigens that can elicit a strong immunological response.

The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed multiple clinical trials, including one Phase 2 clinical trial (OVATION 2), and is currently conducting a Phase 3 clinical trial (OVATION 3). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit www.imunon.com.

Forward-Looking Statements

IMUNON wishes to inform readers that forward-looking statements in this release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding expectations regarding the timing and enrollment of the Company’s clinical trials, the potential of any therapies developed by the Company to fulfill unmet medical needs, the market potential for the Company’s products, if approved, the potential efficacy and safety profile of our product candidates, and the Company’s plans and expectations with respect to its development programs more generally, are forward-looking statements. We generally identify forward-looking statements by using words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure in conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON’s filings with the Securities and Exchange Commission. IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Investors Contact:
Valter Pinto
KCSA Strategic Communications
212-896-1254
imunon@kcsa.com

TKM Grupp AS informed the stock exchange on 11 March 2026 of the completion of a transaction pursuant to which the Group’s subsidiary TKM Auto OÜ acquired 100% of the shares in Rohe Auto AS, 100% of the shares in SKO Motors OÜ and 100% of the shares in SKO Motors Kinnisvara OÜ. Rohe Auto AS and SKO Motors OÜ, acquired through the transaction, have been integrated into the Group’s car segment thereby strengthening the Group’s position in the Estonian automotive market. As a result of the transaction, the Group became the largest Škoda dealer in the Baltics.

Considering the corporate structure and business segments of TKM Grupp AS, it has been decided to merge SKO Motors Kinnisvara OÜ, the real estate company acquired as part of the above-mentioned transaction, with TKM Kinnisvara AS, which belongs to the Group’s real estate segment. To this end, a merger will be carried out whereby TKM Kinnisvara AS (as the acquiring company) will merge SKO Motors Kinnisvara OÜ (as the company being acquired) into itself.

Today, the parties signed the merger agreement in connection with the above-mentioned merger. The merger is expected to be registered in the Commercial Register in November 2026.

Raul Puusepp
Chairman of the Board
Phone: +372 731 5000
info@tkmgrupp.ee

RISHON LE ZION, Israel, Sept. 10, 2026 (GLOBE NEWSWIRE) — BOS Better Online Solutions Ltd. (“BOS” or the “Company”) (NASDAQ: BOSC), an integrator of supply chain technologies for the aerospace, defense, industrial and retail sectors, announced today that it will release financial results for the third quarter of 2026 before the market opens on Monday, November 30, 2026.

Additionally, BOS will host a video conference call on November 30, 2026, at 8:30 a.m. Eastern Time. A question-and-answer session will follow management’s presentation.

To access the video conference meeting, please click on the following link:

https://us06web.zoom.us/j/88403627595?pwd=IvzvcHZooR8CiO7jY4tap56J04OdSQ.1

For those unable to participate in the video conference, a recording of the meeting will be available the next day on the BOS website: www.boscom.com

About BOS

BOS integrates cutting-edge technologies to streamline and enhance supply chain operations for global customers in the aerospace, defense, industrial and retail sectors. The Company operates three specialized divisions:

Supply Chain Division
Distributes and integrates franchised electronic components directly into customer products.

RFID Division
Optimizes customers’ inventory management through state-of-the-art marking and tracking solutions, ensuring real-time visibility and control.

Intelligent Robotics Division
Automates industrial and logistics inventory processes through advanced robotics technologies, improving efficiency and precision.

For more information on BOS Better Online Solutions Ltd., visit www.boscom.com.

Contacts:

Eyal Cohen, CEO
BOS | +972-542525925 | eyalc@boscom.com

Safe Harbor Regarding Forward-Looking Statements

The forward-looking statements contained herein reflect management’s current views with respect to future events and financial performance. These forward-looking statements are subject to certain risks and uncertainties that could cause the actual results to differ materially from those in the forward-looking statements, all of which are difficult to predict and many of which are beyond the control of BOS. These risk factors and uncertainties include, amongst others, the dependency of sales being generated from one or a few major customers, the uncertainty of BOS being able to maintain current gross profit margins, inability to keep up or ahead of technology and to succeed in a highly competitive industry, inability to maintain marketing and distribution arrangements and to expand our overseas markets, uncertainty with respect to the prospects of legal claims against BOS, the effect of exchange rate fluctuations, general worldwide economic conditions, the effect of the ongoing armed conflict and security conditions in Israel and in the region, the continued availability of financing for working capital purposes and to refinance outstanding indebtedness, the risk that a customer order, including the order described herein, may be delayed, modified, or canceled prior to completion of delivery; and additional risks and uncertainties detailed in BOS’ periodic reports and registration statements filed with the US Securities and Exchange Commission. BOS undertakes no obligation to publicly update or revise any such forward-looking statements to reflect any change in its expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

PRESS RELEASE
Paris, 10 September, 2026

Information on the total number of voting rights
and shares forming the share capital

(Article L.233-8 II of the French Commercial Code and
Article 223-16 of the General Regulation of the French Financial Markets Authority)

Date Issued capital Par value Total number of shares Total number of voting rights
Theoretical* Exercisable**
 

August 31, 2026

 

€ 245,607,624 € 1 245,607,624 276,893,345 272,826,627

*In accordance with Article 223-11 of the General Regulation of the French Financial Markets Authority, the total number of theoretical voting rights is calculated on the basis of all shares to which voting rights are attached, including shares deprived of voting rights.
**The total number of exercisable voting rights is calculated without taking into account shares deprived of voting rights.


About Valeo

As a technology company and partner to all automakers and new mobility players, Valeo is innovating to make mobility cleaner, safer and smarter. Valeo enjoys technological and industrial leadership in electrification, driving assistance systems, reinvention of the interior experience and lighting everywhere. These four areas, vital to the transformation of mobility, are the Group’s growth drivers.

Valeo in figures: 20.9 billion euros in sales in 2025 | 100,216 employees, 29 countries, 149 plants, 59 research and development centers, 18 distribution platforms at December 31, 2025.

Valeo is listed on the Paris Stock Exchange.  

Attachment

Transaction in Own Shares

September 09, 2026

• • • • • • • • • • • • • • • •

Shell plc (the ‘Company’) announces that on 09 September 2026 it purchased the following number of Shares for cancellation.

Aggregated information on Shares purchased according to trading venue:

Date of Purchase Number of Shares purchased Highest price paid Lowest price paid Volume weighted average price paid per share Venue Currency
09/09/2026 895,000 £ 35.4500 £ 34.9700 £ 35.2051 LSE GBP
09/09/2026 125,712 £ 35.1100 £ 34.9800 £ 35.0574 Chi-X (CXE) GBP
09/09/2026 – – – – BATS (BXE) GBP
09/09/2026 500,000 € 41.3700 € 40.8500 € 41.1095 XAMS EUR
09/09/2026 – – – – CBOE DXE EUR
09/09/2026 – – – – TQEX EUR

These share purchases form part of the on- and off-market limbs of the Company’s existing share buy-back programme previously announced on 30 July 2026.

In respect of this programme, Goldman Sachs International will make trading decisions in relation to the securities independently of the Company for a period from 30 July 2026 up to and including 23 October 2026.

The on-market limb will be effected within certain pre-set parameters and in accordance with the Company’s general authority to repurchase shares on-market. The off-market limb will be effected in accordance with the Company’s general authority to repurchase shares off-market pursuant to the off-market buyback contract approved by its shareholders and the pre-set parameters set out therein. The programme will be conducted in accordance with Chapter 9 of the UK Listing Rules and Article 5 of the Market Abuse Regulation 596/2014/EU dealing with buy-back programmes (“EU MAR”) and EU MAR as “onshored” into UK law from the end of the Brexit transition period (at 11:00 pm on 31 December 2020)  through the European Union (Withdrawal) Act 2018 (as amended by the European Union (Withdrawal Agreement) Act 2020), and as amended, supplemented, restated, novated, substituted or replaced by the Financial Services Act, 2021 and relevant statutory instruments (including, The Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310)), from time to time (“UK MAR”) and the Commission Delegated Regulation (EU) 2016/1052 (the “EU MAR Delegated Regulation”) and the EU MAR Delegated Regulation as “onshored” into UK law from the end of the Brexit transition period (at 11:00 pm on 31 December 2020) through the European Union (Withdrawal) Act 2018 (as amended by the European Union (Withdrawal Agreement) Act 2020), and as amended, supplemented, restated, novated, substituted or replaced by the Financial Services Act, 2021 and relevant statutory instruments (including, The Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310)), from time to time.

In accordance with EU MAR and UK MAR, a breakdown of the individual trades made by Goldman Sachs International on behalf of the Company as a part of the buy-back programme is detailed below.

Enquiries:

Media International: +44 (0) 207 934 5550; U.S. and Canada: https://www.shell.us/about-us/news-and-insights/media/submit-an-inquiry.html

 

Attachment

Visit Gix Internet website: https://www.gix-internet.com/

TEL AVIV, Israel, Sept. 10, 2026 (GLOBE NEWSWIRE) — Gix Internet Ltd. (Nasdaq: GIXI; TASE: GIX), a dual-listed technology company, today announced the launch of its new corporate website. The website presents the Company’s strategy of developing one intelligent, AI-powered management and orchestration software layer designed to coordinate an organization’s autonomous robots and the people working alongside them. The goal is to provide one common operating environment for robots, people and autonomous systems. Gix’s wholly owned subsidiary, Deliverz.ai, currently deploys this technology in hospital logistics.

The new website is designed to provide hospitals, potential partners and investors with information regarding the Company’s technology, its current commercial deployment and the Company’s plans for potential expansion into additional markets. Gix’s digital advertising activities are conducted through Quantum X Labs Inc., a separately listed company in which Gix holds a strategic minority interest.

Deliverz.ai assigns, manages and tracks internal deliveries of medications, samples and supplies in real time. It coordinates autonomous robots and human transport teams through a single intelligent management layer and is designed to work with existing hospital infrastructure, including elevators, doors and access control. The platform is robot-agnostic, so hospitals can run a hybrid workforce of machines and people without replacing one for the other. Gix’s broader strategy is to create one intelligent management and orchestration layer for physical operations — connecting robots, people and, over time, additional autonomous systems through one control environment. The Company believes that hospital logistics represents an initial commercial application of the platform and that the technology may ultimately be adaptable to other complex operating environments.

At Sheba Medical Center, ranked among the world’s leading hospitals, Deliverz.ai has been in continuous commercial use since December 2025, and, as of the date hereof, has completed more than 7,000 autonomous missions. In the oncology workflow between the pharmacy and treatment units, the deployment cut chemotherapy delivery time from 40 minutes to 14 minutes. Following a successfully completed pilot, Sheba selected Deliverz.ai under a public tender that provides for the potential deployment of up to 30 robots.

In July 2026, Deliverz.ai announced it was introducing the same approach to healthcare organizations in the United States.

Deliverz.ai holds two granted patents in physical-AI navigation, registered in Israel, Europe and Korea, with applications under review in the United States and Japan.

“Our dual listing on Nasdaq and the Tel Aviv Stock Exchange provides Gix with access to a broader investor audience,” said Amir Nardimon, Chief Executive Officer of Gix Internet. “We believe that the launch of our new website is an important step in presenting our technology, commercial operations and growth strategy more clearly to hospitals, potential partners and investors.”

Nardimon added: “Hospitals manage complex internal logistics involving medications, samples and supplies. Our platform is designed to coordinate autonomous robots and human transport teams through a single operating layer. Building on our commercial deployment at Sheba Medical Center, we are pursuing opportunities to introduce this technology to healthcare organizations in the United States.”

Nardimon continued: “Our vision goes beyond managing an individual robot or automating a single workflow. We are building one intelligent management layer for robots, people and autonomous systems – a common operating environment that can decide what needs to move, who or what should perform the task, and how the operation should be coordinated in real time. Healthcare is where we have first proven this approach commercially, but we believe the same management architecture can ultimately be relevant to many complex physical environments.”

The new website is at: https://www.gix-internet.com/

About Gix Internet Ltd.

Gix Internet Ltd. is listed on the Tel Aviv Stock Exchange and, as of September 1, 2026, on the Nasdaq Capital Market under the symbol GIXI. Its operating focus is Deliverz.ai, a wholly owned company that develops an AI-powered management and orchestration layer for robots, people and autonomous systems, commercially proven today in hospital logistics. The platform combines management software with autonomous mobile robots and human couriers to schedule and assign internal deliveries in real time – by location, priority and availability – from a central operations system. It is built for last-mile movement inside complex, high-traffic facilities such as hospitals, is in commercial use at Sheba Medical Center, and is being introduced to U.S. healthcare organizations. Gix’s broader strategy is to extend the same management architecture to additional autonomous systems and complex physical operating environments. Gix also holds a strategic minority stake in Quantum X Labs Inc., a separately listed company. For more information, visit https://www.gix-internet.com/.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Forward-looking statements contained in this press release include, but are not limited to, statements regarding Gix;s strategic and business plans, technology, relationships, objectives and expectations for its business, growth, the impact of trends on and interest in its business, intellectual property, products and its future results, operations and financial performance and condition and may be identified by the use of words such as “may,” “seek,” “will,” “consider,” “likely,” “assume,” “estimate,” “expect,” “anticipate,” “intend,” “believe,” “do not believe,” “aim,” “predict,” “plan,” “project,” “continue,” “potential,” “guidance,” “objective,” “outlook,” “trends,” “future,” “could,” “would,” “should,” “target,” “on track” or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. For example, the Company is using forward-looking statements when it discusses its strategy of developing and expanding its AI-powered orchestration platform, the potential expansion of its technology into additional markets and operating environments, the anticipated capabilities and benefits of its platform, the potential deployment of additional robots pursuant to the Sheba Medical Center tender, the introduction and commercialization of its technology in the United States, and its growth strategy and future business opportunities. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s registration statement of Form 20-F (File No. 001-43362), as amended, as filed with the SEC on June 18, 2026, and in subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Gix is not responsible for the content of third-party websites.

Investor Relations Contact:

Michal Efraty
Investor Relations
michal@efraty.com

300% plus increase in six-month net income to $7.12 per share

Record revenues of $550 million in first half of 2026

Net income of $4.40 per share in Q2 2026

$3.6 billion in minimum contracted revenue

Dynamic growth of 26 vessels under construction, seven of which already delivered

$1.50 in common stock dividends paid in 2026

Tanker Market Fundamentals Remain Strong

ATHENS, Greece, Sept. 10, 2026 (GLOBE NEWSWIRE) — TEN, Ltd (NYSE: TEN) (the “Company”) today reported results (unaudited) for the six months and the second quarter ended June 30, 2026.

FIRST HALF 2026 SUMMARY RESULTS
TEN’s fleet generated record gross revenues of $551.4 million, an increase of $161.0 million compared to the first half of 2025.

Adjusted EBITDA for the first half of 2026 was at approximately $324.1 million from $193.2 million in the first six months of 2025.

The net income for the first half of 2026 reached $228.1 million (including $38 million in capital gains), equivalent to $7.12 per share from $1.70 per share in the equivalent 2025 six-month period, an increase of 318%.

Fleet utilization remained unchanged from the corresponding period in 2025 at 96.5%.

The average Time Charter Equivalent (TCE) per vessel per day for the first half of 2026 rose to $43,503, compared with $30,754 in the first half of 2025, representing a 41% increase, driven by the continued strength of the tanker markets.

Vessel operating expenses rose modestly and in line with expectations to $111.0 million, from $102.3 million in the first half of 2025, primarily due to six vessels undergoing scheduled drydocking’s, one being an LNG carrier during the first half of 2026.

Total operating expenses per vessel per day remained at a still competitive $10,298.

Depreciation and amortization totaled $90.4 million, attributable to the operation of newer and larger vessel classes to the fleet.

Total bank debt as of June 30, 2026 was $2.0 billion from $1.8 billion at December 31, 2025, reflecting fleet growth. TEN’s cash balances increased to $466.1 million, $168.0 million higher than the end of December 2025.

Interest and finance costs for the first half of 2026 amounted to $43.4 million, $5.6 million lower than the 2025 first-half level, the result of lower spreads and lower global interest rates achieved on new and refinanced loans. These costs were partially offset by interest income received in the first half of 2026 of $5.6 million.

Q2 2026 SUMMARY RESULTS
TEN’s gross revenues during the second quarter of 2026 reached $298.4 million, an increase of $105.1 million, or 54%, over the corresponding period in 2025.

Adjusted EBITDA for the second quarter of 2026 increased to $170.4 million, 81% higher than the 2025 second quarter level.

Net income in the second quarter of 2026 reached $139.3 million (inclusive of $38 million capital gains), equivalent to $4.40 per share, from $0.67 per share in the second quarter of 2025 which had no capital gains, an increase of 500% plus.

Average TCE per vessel per day in the second quarter of 2026 reached $46,100, 50% higher than the equivalent 2025 period, supported by high fleet utilization rates of nearly 95% amid favorable market fundamentals and geopolitical disruptions.

Fleet operating expenses amounted to $57.7 million, just $5.0 million above the second quarter 2025 level, primarily due to four vessels, including two suezmax tankers, undergoing scheduled drydocking’s during the quarter, compared with three in the corresponding 2025 period.

As a result, operating expenses per vessel per day in the second quarter of 2026 were $10,640.

Depreciation and amortization expenses during the second quarter of 2026 were in line with the increased number of vessels in the fleet at $46.3 million.

Consistent with the first half trend, interest and finance costs in the second quarter of 2026 decreased by $2.3 million from the corresponding 2025 period to settle at $22.6 million, benefiting from lower borrowing spreads and lower global interest rates, while interest income totaled $3.4 million.

SUBSEQUENT EVENTS
As previously announced, on July 28, 2026, TEN took delivery of the DP2 suezmax shuttle tanker Anfield DP from Samsung Heavy Industries Co., Ltd in South Korea, the third in a series of 12 DP2 shuttle tankers under construction at that yard. The vessel commenced a 10-year employment to a US oil major, with charter options to extend the charter until the vessel’s 20th year anniversary. Assuming charterers employ the vessel to the maximum duration, the expected gross revenues should approach $500 million.

As part of its ongoing fleet renewal program, in August 2026 TEN concluded the sale of two 2006-built suezmax tankers, the Alaska and Archangel, for net proceeds of $100 million.

CORPORATE AFFAIRS – COMMON STOCK DIVIDEND

In July 2026, TEN distributed to common shareholders a second semi-annual dividend, amounting to $1.00 per share, following a $0.50 per share payment in February 2026. A total distribution of $1.50 per share in 2026. The Company intends to announce the first semi-annual dividend payment of 2027 in November 2026.

Since the Company’s NYSE listing in 2002, TEN has consistently demonstrated its commitment to reward shareholders, and will have distributed, until the end of 2026 over $1.0 billion in cumulative common and preferred share dividends.

CORPORATE AFFAIRS – SERIES E PREFERRED SHARES

The Company’s 9.25% Series E Preferred Shares become redeemable at the election of the Company on May 28, 2027, and the Company currently expects that it may elect to redeem, all or a portion of, such Series E Preferred Shares on the above stated date. This disclosure does not constitute a notice of redemption, and there can be no assurance as to the amount, if any, of the Series E Preferred Shares that will be redeemed.

CORPORATE STRATEGY
Geopolitical developments around the globe continue to dictate the pace of the ongoing tanker rally which, coupled with favorable market fundamentals, is creating promising conditions for a sustained healthy market going forward.

Taking advantage of the increased ton-mile demand dislocations TEN secured attractive long-term employment to meet client requirements while solidifying the Company’s significant revenue backlog.

In addition, and in line with the stated fleet renewal strategy and considering the size of the new building program, the majority of which ordered against long-term employment, TEN continues to divest from older vessels. The sale of the 2016-built VLCC Ulysses and the two 2006-built suezmax tankers Alaska and Archangel, are a testament to that approach.

With a substantial cash balance of $466 million as of June 30, 2026, which has continued to grow thereafter, the Company remains well positioned to continue its fleet renewal and increasingly reward its shareholders.

“These results underscore the strength of TEN’s diversified fleet and flexible employment strategy which along with vessel sales, affords us the ability to generate healthy cash flows to reward our shareholders, while continuing our dynamic fleet modernization,” stated Mr. George Saroglou, President of TEN. “The company’s well-timed growth program, the largest in its history, will propel TEN going forward and solidify its position as a first-choice partner to the major energy concerns,” Mr. Saroglou concluded.

TEN’s CURRENT NEWBUILDING PROGRAM

# Name Type Delivery (exp) Status Employment
CONVENTIONAL TANKERS
1 Dr Irene Tsakos Suezmax – Scrubber Fitted Q2 2025 DELIVERED Yes
2 Silia T Suezmax – Scrubber Fitted Q4 2025 DELIVERED Yes
3 Delos T MR – Scrubber Fitted Q1 2026 DELIVERED Yes
4 Dion MR – Scrubber Fitted Q1 2026 DELIVERED Yes
5 AMAZONA Panamax LR1 – Scrubber Fitted Q2 2027 Under Construction TBA
6 TBN Panamax LR1 – Scrubber Fitted Q3 2027 Under Construction TBA
7 TBN Panamax LR1 – Scrubber Fitted Q4 2027 Under Construction TBA
8 CHAIRMAN DJS VLCC – Scrubber Fitted Q4 2027 Under Construction TBA
9 TBN VLCC – Scrubber Fitted Q1 2028 Under Construction TBA
10 TBN VLCC – Scrubber Fitted Q2 2028 Under Construction TBA
11 TBN Panamax LR1 – Scrubber Fitted Q3 2028 Under Construction TBA
12 TBN Panamax LR1 – Scrubber Fitted Q3 2028 Under Construction TBA
SHUTTLE TANKERS
13 Athens 04 DP2 Shuttle Tanker Q2 2025 DELIVERED Yes
14 Paris 24 DP2 Shuttle Tanker Q3 2025 DELIVERED Yes
15 Anfield DP DP2 Shuttle Tanker Q3 2026 DELIVERED Yes
16 ARIANO SUASSUNA DP DP2 Shuttle Tanker Q3 2027 Under Construction Yes
17 ELZA SOARES DP DP2 Shuttle Tanker Q4 2027 Under Construction Yes
18 MARIA FIRMINA DP DP2 Shuttle Tanker Q1 2028 Under Construction Yes
19 CAROLINA DE JESUS DP DP2 Shuttle Tanker Q2 2028 Under Construction Yes
20 IPANEMAS DP DP2 Shuttle Tanker Q3 2028 Under Construction Yes
21 MARACANA DP DP2 Shuttle Tanker Q3 2028 Under Construction Yes
22 CORINTHIANS DP DP2 Shuttle Tanker Q4 2028 Under Construction Yes
23 DR SOCRATES DP DP2 Shuttle Tanker Q4 2028 Under Construction Yes
24 TBN DP2 Shuttle Tanker Q4 2028 Under Construction Yes
LNG CARRIERS
25 NY KNICKS LNG Carrier Q3 2028 Under Construction TBA
26 TBN LNG Carrier Q1 2029 Under Construction TBA


ABOUT TEN LTD.

Founded in Bermuda in 1993 and celebrating 33 years as a public company, 24 of which on the NYSE, TEN is one of the first and most established public shipping companies in the world. TEN’s diversified pro-forma energy fleet currently consists of 81 vessels, totaling approx. 10.5 million dwt.

FORWARD-LOOKING STATEMENTS
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those predicted by such forward-looking statements. TEN undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Conference Call Details:
As announced previously, today, Thursday, September 10, 2026, at 10:00 a.m. Eastern Time, TEN will host a conference call to review the results as well as management’s outlook for the business. The call, which will be hosted by TEN’s senior management, may contain information beyond what is included in the earnings press release.

Participants should dial into the call 10 minutes before the scheduled time using the following numbers: 877- 405- 1226 (US Toll-Free Dial In) or +1 201-689-7823 (US and Standard International Dial In). Please quote “Tsakos” to the operator and/or conference ID 13762392.
Click here for additional participant International Toll-Free access numbers.

Alternatively, participants can register for the call using the call me option for a faster connection to join the conference call. You can enter your phone number and let the system call you right away. Click here for the call me option.

Simultaneous Slides and Audio Webcast:
There will also be a live, and then archived, webcast of the conference call and accompanying slides, available through the Company’s website. To listen to the archived audio file, visit our website www.tenn.gr and click on Webcasts & Presentations under our Investor Relations page. Participants to the live webcast should register on the website approximately 10 minutes prior to the start of the webcast.

For further information, please contact:

Tsakos Energy Navigation Ltd.
George Saroglou
President & COO
+30210 94 07 710
gsaroglou@tenn.gr

Investor Relations / Media
Capital Link, Inc.
Nicolas Bornozis/ Markella Kara
+212 661 7566
ten@capitallink.com

















TSAKOS ENERGY NAVIGATION LIMITED AND SUBSIDIARIES
Selected Consolidated Financial and Other Data
(In Thousands of U.S. Dollars, except share, per share and fleet data)



















Three months ended

Six months ended



June 30 (unaudited)

June 30 (unaudited)

STATEMENT OF OPERATIONS DATA
2026



2025


2026



2025


















Voyage revenues $ 298,405


$ 193,309

$ 551,367


$ 390,360


































Voyage expenses
52,126



31,917


81,972



67,980


Charter hire expense
2,646



3,321


6,032



6,603


Vessel operating expenses
57,690



52,704


110,954



102,310


Depreciation and amortization
46,295



42,089


90,443



83,220


General and administrative expenses
14,792



13,237


27,236



23,143


Gain on sale of vessels
(37,870 )


–


(37,870 )


(3,553 )

Total expenses
135,679



143,268


278,767



279,703


















     Operating income
162,726



50,041


272,600



110,657


















Interest and finance costs, net
(22,643 )


(24,978 )

(43,430 )


(48,980 )

Interest income
3,405



3,231


5,606



5,538


Other, net
(12 )


(4 )

(33 )


(23 )

Total other expenses, net
(19,250 )


(21,751 )

(37,857 )


(43,465 )

     Net income
143,476



28,290


234,743



67,192


















      Less: Net income attributable to the noncontrolling interest
(4,176 )


(1,457 )

(6,601 )


(2,648 )

Net income attributable to Tsakos Energy Navigation Limited $ 139,300


$ 26,833

$ 228,142


$ 64,544


















Effect of preferred dividends
(6,750 )


(6,750 )

(13,500 )


(13,500 )

Undistributed and distributed income allocated to non-vested restricted common stock (684 )


(313 )

(1,108 )


(513 )

Net income attributable to common stockholders of Tsakos Energy Navigation Limited $ 131,866


$ 19,770

$ 213,534


$ 50,531


Earnings per share, basic and diluted attributable to Tsakos Energy Navigation Limited common stockholders $ 4.40


$ 0.67

$ 7.12


$ 1.70


Weighted average number of shares, basic and diluted
29,972,103



29,661,103


29,972,103



29,661,103


















BALANCE SHEET DATA
June 30


December 31










2026


2025








Cash
466,143



298,129









Other assets
286,240



197,009









Vessels, net
3,155,282



3,156,075









Advances for vessels under construction
470,050



301,868









     Total assets       $ 4,377,715


$ 3,953,081

























Debt and other financial liabilities, net of deferred finance costs
2,102,177



1,920,975









Other liabilities
220,881



169,101









Stockholders’ equity
2,054,657



1,863,005









     Total liabilities and stockholders’ equity       $ 4,377,715


$ 3,953,081











































































Three months ended

Six months ended

OTHER FINANCIAL DATA
June 30

June 30



2026



2025


2026



2025


Net cash provided by operating activities $ 183,986


$ 63,794

$ 281,167


$ 115,944


Net cash provided by (used in) investing activities $ 3,763


$ (233,479 )
$ (248,312 )

$ (236,124 )

Net cash (used in) provided by financing activities $ (43,022 )

$ 107,327

$ 135,159


$ 59,088


















TCE per ship per day $ 46,100


$ 30,767

$ 43,503


$ 30,754


















Operating expenses per ship per day $ 10,640


$ 9,982

$ 10,298


$ 9,743


Vessel overhead costs per ship per day $ 2,558


$ 2,347

$ 2,370


$ 2,063




13,198



12,329


12,668



11,806


















FLEET DATA






























Average number of vessels during period
63.5



62.0


63.5



62.0


Number of vessels at end of period
64.0



63.0


64.0



63.0


Average age of fleet at end of period Years 10.5



10.2


10.5



10.2


Dwt at end of period (in thousands)
7,702



7,766


7,702



7,766


















Time charter employment – fixed rate Days 3,569



2,969


7,197



5,841


Time charter and pool employment – variable rate Days 1,263



1,771


2,731



3,518


Period employment coa at market rates Days 0



0


0



0


Spot voyage employment at market rates Days 652



708


1,165



1,507


     Total operating days
5,484



5,448


11,093



10,866


     Total available days
5,783



5,641


11,490



11,216


      Utilization
94.8 %


96.6 %

96.5 %


96.9 %

















Non-GAAP Measures

Reconciliation of Net income to Adjusted EBITDA



















Three months ended

Six months ended



June 30

June 30



2026



2025


2026



2025


















Net income attributable to Tsakos Energy Navigation Limited $ 139,300


$ 26,833

$ 228,142


$ 64,544


Depreciation and amortization
46,295



42,089


90,443



83,220


Interest Expense
22,643



24,978


43,430



48,980


Gain on sale of vessels
(37,870 )


–


(37,870 )


(3,553 )

Adjusted EBITDA $ 170,368


$ 93,900

$ 324,145


$ 193,191


















The Company reports its financial results in accordance with U.S. generally accepted accounting principles (GAAP). However, management believes that certain non-GAAP measures used within the financial community may provide users of this financial information additional meaningful comparisons between current results and results in prior operating periods as well as comparisons between the performance of Shipping Companies. Management also uses these non-GAAP financial measures in making financial, operating and planning decisions and in evaluating the Company’s performance. We are using the following Non-GAAP measures:

(i) TCE which represents voyage revenue less voyage expenses, is divided by the number of operating days less 63 days lost for the second quarter and 137 days for the first half of 2026 as a result of calculating revenue on a loading to discharge basis, compared to 84 days lost for the second quarter and 148 days for the first half of 2025.

(ii) Vessel overhead costs are General & Administrative expenses, which also include Management fees, Stock compensation expense and Management incentive award.

(iii) Operating expenses per ship per day which exclude Management fees, General & Administrative expenses, Stock compensation expense and Management incentive award.

(iv) Adjusted EBITDA. See above for reconciliation to net income.

Non-GAAP financial measures should be viewed in addition to and not as an alternative for, the Company’s reported results prepared in accordance with GAAP.

The Company does not incur corporation tax.






















SOUTHAMPTON, Pa., Sept. 10, 2026 (GLOBE NEWSWIRE) — Environmental Tectonics Corporation (OTCID: ETCC) (“ETC” or the “Company”) today announced that it has completed the sale of 100% of the equity interests of its wholly owned Polish subsidiary, ETC-PZL Aerospace Industries sp.z o.o. (“ETC-PZL) to Fabryka Artykułów Turystycznych i Sportowych Polsport sp. z o.o., a limited liability company incorporated under the laws of the Republic of Poland.

The transaction is part of the Company’s ongoing efforts to focus its resources on its core businesses and strategically align its operations with its long term objectives. The Company expects the transaction to have a positive impact on its ongoing consolidated financial results.

ETC and ETC-PZL entered into a separate 10-year Cooperation Agreement under which ETC-PZL will serve as a preferred supplier to the Company for certain products manufactured by ETC-PZL. Under the agreement, the Company retains the ability to manufacture the applicable products internally if the parties are unable to reach mutually acceptable commercial terms, if ETC-PZL is unable to meet the Company’s supply requirements or if ETC-PZL is unable to supply based on certain applicable regulatory requirements.

Robert L. Laurent, Jr., ETC’s Chief Executive Officer and President stated, “I look forward to continuing the longstanding strategic partnership with ETC-PZL. This transaction provides ETC a meaningful opportunity to improve operating results while maintaining continuity of supply and the flexibility to manufacture products internally.”

About ETC

ETC designs, manufactures, and sells software-driven products and services used to recreate and monitor the physiological effects of motion on humans, and equipment to control, modify, simulate and measure environmental conditions. Our products include aircrew training systems (aeromedical, tactical combat, and general), disaster management systems, sterilizers (steam and gas), environmental testing and simulation systems, and other products that involve similar manufacturing techniques and engineering technologies. ETC’s unique ability to offer complete systems, designed and produced to high technical standards, sets it apart from its competition. ETC’s headquarters is in Southampton, PA. For more information about ETC, visit http://www.etcusa.com/.

Forward-looking Statements
This news release contains forward-looking statements, which are based on management’s expectations and are subject to uncertainties and changes in circumstances. Words and expressions reflecting something other than historical fact are intended to identify forward-looking statements, and these statements may include terminology such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “estimate”, “future”, “predict”, “potential”, “intend”, or “continue”, and similar expressions. We base our forward-looking statements on our current expectations and projections about future events or future financial performance. Our forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about ETC and its subsidiaries that may cause actual results to be materially different from any future results implied by these forward-looking statements. We caution you not to place undue reliance on these forward-looking statements. 

CONTACT: Contact: Tim Kennedy, CFO
Phone: (215) 355-9100 
E-mail: info@etcusa.com 

ATHENS, Greece, Sept. 10, 2026 (GLOBE NEWSWIRE) — IMPERIAL PETROLEUM INC. (NASDAQ: IMPP; the “Company”), a ship-owning company providing petroleum products, crude oil and dry bulk seaborne transportation services, announced today its unaudited financial and operating results for the second quarter and six months ended June 30, 2026.

OPERATIONAL AND FINANCIAL HIGHLIGHTS

  • Fleet operational utilization of 73.5% in Q2 26’.
  • Approximately 50% of total fleet calendar days in Q2 26’ were dedicated to time charter activity while approximately 39% were dedicated to spot activity.
  • Delivery of the dry bulk carrier, Eco Crossfire (2012 built), on April 3, 2026 and delivery of the drybulk carrier, Outrider (2016 built), on August 21, 2026.
  • Sale of our tanker Suez Enchanted (2007 built) to third parties, on August 7, 2026, creating a net gain on sale of approximately $32 million.
  • All-time high quarterly revenues of $87.1 million in Q2 26’ compared to $61.7 million in Q1 26’ and $36.3 million in Q2 25’, representing a 41.2% increase and a 139.9% increase, respectively.
  • Near all-time high operating income of $33.4 million in Q2 26’ marking a $6.9 million or 26.0% increase compared to Q1 26’ and a $25.2 million or 307.3% increase compared to Q2 25’.
  • Net income of $34.8 million in Q2 26’- the second best in our history- compared to $28.0 million in Q1 26’, and $12.8 million in Q2 25’, representing a 24.3% and 171.9% increase, respectively.
  • Basic EPS of $0.75 in Q2 26’ and $1.34 for 6M 2026.
  • EBITDA1 of $41.2 million for Q2 26’.
  • Continued enhancement of our liquidity through efficient vessel operations; cash and cash equivalents including time deposits of $245.2 million as of June 30, 2026 compared to $179.1 million as of December 31, 2025 – corresponding to an increase of 36.9%. Our current cash base is about $260 million.
  • For the 6M’ 2026 our Net Income came in at $62.8 million, already exceeding our 12M’ 2025 net income  performance of $50.0 million.

Second Quarter 2026 Results: 

  • Revenues for the three months ended June 30, 2026, amounted to $87.1 million, an increase of $50.8 million or 139.9%, compared to revenues of $36.3 million for the three months ended June 30, 2025, primarily due to a 6.9 vessel increase in the average number of vessels in our fleet, along with an increase in both tanker and drybulk rates driven by geopolitical tensions, mostly affecting the tanker vessels, and favorable market dynamics in the drybulk market.
  • Voyage expenses and vessels’ operating expenses for the three months ended June 30, 2026, were $22.1 million and $14.4 million, respectively, compared to $10.7 million and $8.4 million, respectively, for the three months ended June 30, 2025. The $11.4 million increase in voyage expenses is mainly attributed to increased bunker costs by mainly due to an increase in spot days by 58.4% and increased bunkers’ prices. The $6.0 million increase in vessels’ operating expenses is primarily due to the increase of our fleet by an average of 6.9 vessels.
  • Drydocking costs for the three months ended June 30, 2026 and 2025 were $7.5 million and $1.7 million, respectively. During the three months ended June 30, 2026, six vessels underwent drydocking whereas during the three months ended June 30, 2025, one suezmax tanker and one supramax drybulk carrier underwent drydocking.
  • General and administrative costs for the three months ended June 30, 2026 and 2025, were $1.1 million in each period.
  • Depreciation for the three months ended June 30, 2026 and 2025, was $8.2 million and $5.7 million, respectively. The change is attributable to the increase in the average number of vessels in our fleet.
  • Management fees for the three months ended June 30, 2026 and 2025, were $0.8 million and $0.6 million, respectively. The change is attributable to the increase in the average number of vessels in our fleet.
  • Interest and finance costs for the three months ended June 30, 2026 and 2025, were $0.4 million and $0.8 million, respectively. The $0.4 million of costs for the three months ended June 30, 2026 related mainly to accrued interest expense – related party in connection with the $19.2 million and $12.3 million portions of the acquisition price of our bulk carriers, Post Marvel and Eco Crossfire, respectively, which were completely settled in the third quarter of 2026. The $0.8 million of costs for the three months ended June 30, 2025 related mainly to accrued interest expense – related party in connection with our last nine vessel acquisitions, for which the purchase agreements allowed vessel repayment to take place within up to one year from the agreement date. For accounting purposes, the outstanding balances payable on the vessels were required to be allocated between principal and imputed interest, despite the fact that no interest was contractually charged by the sellers. The total amount ultimately paid remains consistent with the originally agreed purchase prices.
  • Interest income for the three months ended June 30, 2026, was $2.1 million as compared to $2.3 million for the three months ended June 30, 2025. The $0.2 million decrease is mainly attributed to a period on period decline in time deposit rates and amounts placed in time deposits.
  • Foreign exchange (loss)/gain for the three months ended June 30, 2026, was a loss of $0.6 million as compared to a gain of $3.0 million for the three months ended June 30, 2025. The $0.6 million foreign exchange loss for the three months ended June 30, 2026 is mainly attributed to the weakening of the Euro currency against the Dollar at the end of the three months ended June 30, 2026 when compared to the respective currency values prevailing at the end of March 2026.
  •  As a result of the above, for the three months ended June 30, 2026, the Company reported net income of $34.8 million, compared to net income of $12.8 million for the three months ended June 30, 2025. Dividends paid on Series A Preferred Shares amounted to $0.4 million for the three months ended June 30, 2026. The weighted average number of shares of common stock outstanding, basic, for the three months ended June 30, 2026 was 45.4 million. Earnings per share, basic and diluted, for the three months ended June 30, 2026 amounted to $0.75 and $0.70, respectively, compared to earnings per share, basic and diluted, of $0.36 and $0.35, respectively, for the three months ended June 30, 2025.
  •  Adjusted net income1 was $35.3 million corresponding to an Adjusted EPS1, basic of $0.76 for the three months ended June 30, 2026 compared to an Adjusted net income of $13.4 million, or an Adjusted EPS, basic, of $0.38 for the same period of last year.
  •  EBITDA1 for the three months ended June 30, 2026 amounted to $41.2 million, while Adjusted EBITDA1 for the three months ended June 30, 2026 amounted to $41.7 million.
  • An average of 21.0 vessels were owned by the Company during the three months ended June 30, 2026 compared to 14.1 vessels for the same period of 2025.

Six Months 2026 Results:

  • Revenues for the six months ended June 30, 2026 amounted to $148.8 million, an increase of $80.4 million or 117.5%, compared to revenues of $68.4 million for the six months ended June 30, 2025, primarily due to a 7.4 vessel increase in the average number of vessels in our fleet, along with an increase in tanker rates noticeable from the beginning of 2026 and drybulk rates which mostly improved in the second quarter of 2026.
  • Voyage expenses and vessels’ operating expenses for the six months ended June 30, 2026, were $34.9 million and $25.6 million, respectively, compared to $21.2 million and $15.5 million, respectively, for the six months ended June 30, 2025. The $13.7 million increase in voyage expenses is mainly attributed to an increase in spot days by 40.3%. The $10.1 million increase in vessels’ operating expenses is primarily due to the increase in the average number of vessels in our fleet by 7.4 vessels.
  • Drydocking costs for the six months ended June 30, 2026 and 2025, were $9.0 million and $1.7 million, respectively. During the six months ended June 30, 2026, seven vessels underwent drydocking whereas during the six months ended June 30, 2025, one suezmax tanker and one supramax drybulk carrier underwent drydocking.
  • General and administrative costs for the six months ended June 30, 2026 and 2025, were $2.2 million and $2.3 million, respectively. This decrease is mainly attributed to the decrease in stock-based compensation costs.
  • Depreciation for the six months ended June 30, 2026 was $16.1 million, a $5.4 million increase from $10.7 million for the same period of last year, due to the increase in the average number of our vessels.
  • Management fees for the six months ended June 30, 2026 and 2025, were $1.6 million and $1.0 million, respectively. The change is attributable to the increase in the average number of vessels in our fleet.
  • Interest and finance costs for the six months ended June 30, 2026 and 2025, were $0.6 million and $1.4 million, respectively. The $0.6 million of costs for the six months ended June 30, 2026 related mainly to accrued interest expense – related party in connection with the $19.2 million and $12.3 million portions of the acquisition prices of our bulk carriers, Post Marvel and Eco Crossfire, respectively, which were completely settled in the third quarter of 2026. The $1.4 million of costs for the six months ended June 30, 2025 related mainly to accrued interest expense – related party in connection with our last nine vessel acquisitions, for which the purchase agreements allowed vessel repayment to take place within up to one year from the agreement date. For accounting purposes, the outstanding balances payable on the vessels were required to be allocated between principal and imputed interest, despite the fact that no interest was contractually charged by the sellers. The total amount ultimately paid remains consistent with the originally agreed purchase prices.
  • Interest income for the six months ended June 30, 2026 and 2025, was $3.9 million and $4.5 million, respectively. The $0.6 million decrease is mainly attributed to a decline in time deposit rates and amounts placed in time deposits.
  • Foreign exchange (loss)/gain for the six months ended June 30, 2026 was a loss of $0.8 million as compared to a gain of $4.7 million for the six months ended June 30, 2025. The $0.8 million foreign exchange loss for the six months ended June 30, 2026 is mainly attributed to the weakening of the Euro currency against the US Dollar at the end of the six months ended June 30, 2026 when compared to the respective currency values prevailing at the end of the year 2025.
  • As a result of the above, the Company reported net income for the six months ended June 30, 2026 of $62.8 million, compared to a net income of $24.1 million for the six months ended June 30, 2025. The weighted average number of shares outstanding, basic, for the six months ended June 30, 2026 was 45.3 million. Earnings per share, basic and diluted, for the six months ended June 30, 2026 amounted to $1.34 and $1.27, respectively compared to earnings per share, basic and diluted, of $0.67 and $0.65 for the six months ended June 30, 2025.
  • Adjusted Net Income was $63.9 million corresponding to an Adjusted EPS, basic, of $1.37 for the six months ended June 30, 2026 compared to an Adjusted Net Income of $25.6 million, or an Adjusted EPS, basic, of $0.72, basic, for the same period of last year.
  • EBITDA for the six months ended June 30, 2026 amounted to $75.6 million while Adjusted EBITDA for the six months ended June 30, 2026 amounted to $76.7 million. Reconciliations of Adjusted Net Income, EBITDA and Adjusted EBITDA to Net Income are set forth below.
  • An average of 20.4 vessels were owned by the Company during the six months ended June 30, 2026 compared to 13.0 vessels for the same period of 2025.
  • As of June 30, 2026, cash and cash equivalents including time deposits amounted to $245.2 million and total debt amounted to nil.

1 EBITDA, Adjusted EBITDA, Adjusted Net Income and Adjusted EPS are non-GAAP measures. Refer to the reconciliation of these measures to the most directly comparable financial measure in accordance with GAAP set forth later in this release. Reconciliations of Adjusted Net Income, EBITDA and Adjusted EBITDA to Net Income are set forth below.

Fleet Employment Table

As of September 10, 2026, the profile and deployment of our fleet is the following:

Name Year Country Vessel Size Vessel Employment Expiration of
  Built Built (dwt) Type Status Charter (1)
Tankers            
Magic Wand 2008 Korea 47,000 MR product tanker Spot  
Clean Thrasher 2008 Korea 47,000 MR product tanker Spot  
Clean Sanctuary 2009 Korea 46,000 MR product tanker Time Charter September 26
Clean Nirvana 2008 Korea 50,000 MR product tanker Spot  
Clean Justice 2011 Japan 46,000 MR product tanker Time Charter September 27
Aquadisiac 2008 Korea 51,000 MR product tanker Spot  
Clean Imperial 2009 Korea 40,000 MR product tanker Spot  
Suez Protopia 2008 Korea 160,000 Suezmax tanker Spot  
Drybulk Carriers            
Eco Wildfire 2013 Japan 33,000 Handysize drybulk Time Charter October 26
Glorieuse 2012 Japan 38,000 Handysize drybulk Time Charter September 26
Neptulus 2012 Japan 33,000 Handysize drybulk Time Charter October 26
Supra Pasha 2012 Japan 56,000 Supramax drybulk Time Charter September 26
Supra Monarch 2011 Japan 56,000 Supramax drybulk Spot  
Supra Baron 2009 Japan 56,000 Supramax drybulk Time Charter September 26
Supra Sovereign 2012 Japan 56,000 Supramax drybulk Time Charter November 26
Supra Duke 2011 Japan 56,000 Supramax drybulk Spot  
Eco Sikousis 2008 Japan 82,000 Kamsarmax drybulk Time Charter September 26
Eco Czar 2009 Japan 82,000 Kamsarmax drybulk Time Charter October 26
Post Marvel 2013 Japan 96,000 Post Panamax Time Charter October 26
Eco Crossfire 2012 Japan 33,000 Handysize drybulk Time Charter September 26
Outrider 2016 Japan 33,000 Handysize drybulk Spot  
Fleet Total (2)     1,197,000 dwt      

(1)
(2)
Earliest date charters could expire.
We have agreements to acquire an additional three handysize drybulk carriers of 107,400 dwt aggregate capacity and a product tanker of 50,000 dwt capacity, with deliveries scheduled in 2026.


CEO
Harry Vafias Commented

Our exceptional second quarter and first half of 2026 demonstrate the power of our commercial strategy and disciplined execution. By securing record revenues of $87.1 million for Q2 26’, expanding our fleet toward a 25-vessel target while remaining debt free, we have driven net income for the first six months to a remarkable $62.8 million, already surpassing our profitability for the entirety of 2025. Backed by a solid balance sheet and with cash to date in the order of approximately $260 million and a fleet value anticipated to increase with our upcoming vessel additions, we are well equipped to navigate shifting geopolitical landscapes. Imperial Petroleum is in a prime position to produce strong results, while holding a flawless balance sheet and a track record of creating value through the Company’s growth and strategic asset management.

Conference Call details:

On September 10, 2026 at 10:00 am ET, the company’s management will host a conference call to discuss the results and the company’s operations and outlook.

Online Registration:

Conference call participants should pre-register using the link below to receive the dial-in numbers and a personal PIN, which are required to access the conference call.

https://register-conf.media-server.com/register/BIe85f8402e2104ed2803a92fc451f9847

Slides and audio webcast:
There will also be a live and then archived webcast of the conference call, through the IMPERIAL PETROLEUM INC. website (www.ImperialPetro.com). Participants to the live webcast should register on the website approximately 10 minutes prior to the start of the webcast.

About IMPERIAL PETROLEUM INC.

IMPERIAL PETROLEUM INC. is a ship-owning company providing petroleum products, crude oil and drybulk seaborne transportation services. The Company owns a total of twenty-one vessels on the water – seven M.R. product tankers, one suezmax tanker, five handysize drybulk carriers, five supramax drybulk carriers, two kamsarmax drybulk vessels and a post panamax drybulk carrier – with a total capacity of approximately 1,197,000 deadweight tons (dwt) and has contracted to acquire an additional three handysize drybulk carriers and a product tanker of 157,400 dwt aggregate capacity. Following these deliveries, the Company’s fleet will count a total of 25 vessels with an aggregate capacity of about 1.3 million dwt. IMPERIAL PETROLEUM INC.’s shares of common stock and 8.75% Series A Cumulative Redeemable Perpetual Preferred Stock are listed on the Nasdaq Capital Market and trade under the symbols “IMPP” and “IMPPP,” respectively.

Forward-Looking Statements

Matters discussed in this release may constitute forward-looking statements. Forward-looking statements reflect our current views with respect to future events and financial performance and may include statements concerning plans, objectives, goals, strategies, future events or performance, including our intentions relating to fleet growth and financing, and outlook for our shipping sectors and vessel earnings, and underlying assumptions and other statements, which are other than statements of historical facts. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, management’s examination of historical operating trends, data contained in our records and other data available from third parties. Although IMPERIAL PETROLEUM INC. believes that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, IMPERIAL PETROLEUM INC. cannot assure you that it will achieve or accomplish these expectations, beliefs or projections. Important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include the strength of world economies and currencies, geopolitical conditions, including any trade disruptions resulting from tariffs and other protectionist measures imposed by the United States or  other countries,  general market conditions, including changes in charter hire rates and vessel values, charter counterparty performance, changes in demand that may affect attitudes of time charterers to scheduled and unscheduled drydockings, changes in IMPERIAL PETROLEUM INC’s operating expenses, including bunker prices, drydocking and insurance costs, ability to complete the acquisitions of our four contracted vessels and to fund the purchase price for these and other recently acquired vessels, ability to obtain financing and comply with covenants in our financing arrangements, actions taken by regulatory authorities, potential liability from pending or future litigation, domestic and international political conditions, the conflict in Ukraine and related sanctions, the conflicts in the Middle East, potential disruption of shipping routes due to ongoing attacks by Houthis in the Red Sea and Gulf of Adenand the effective closure of the Persian Gulf, including the Strait of Hormuz, due to the conflict between Iran and the U.S. and Israel, or accidents and political events or acts by terrorists.

Risks and uncertainties are further described in reports filed by IMPERIAL PETROLEUM INC. with the U.S. Securities and Exchange Commission.

Fleet List and Fleet Deployment
For information on our fleet and further information:
Visit our website at www.ImperialPetro.com

Company Contact:
Fenia Sakellaris
IMPERIAL PETROLEUM INC.
E-mail: info@ImperialPetro.com

Fleet Data:
The following key indicators highlight the Company’s operating performance during the periods ended June 30, 2025 and June 30, 2026.

 FLEET DATA Q2 2025 Q2 2026 6M 2025 6M 2026
Average number of vessels (1) 14.1 21.0 13.0 20.4
Period end number of owned vessels in fleet 19 21 19 21
Total calendar days for fleet (2) 1,284 1,909 2,355 3,698
Total voyage days for fleet (3) 1,237 1,704 2,304 3,468
Fleet utilization (4) 96.3% 89.3% 97.8% 93.8%
Total charter days for fleet (5) 764 955 1,268 2,014
Total spot market days for fleet (6) 473 749 1,036 1,454
Fleet operational utilization (7) 83.1% 73.5% 83.4% 80.9%

1) Average number of vessels is the number of owned vessels that constituted our fleet for the relevant period, as measured by the sum of the number of days each vessel was a part of our fleet during the period divided by the number of calendar days in that period.
2) Total calendar days for fleet are the total days the vessels we operated were in our possession for the relevant period including off-hire days associated with major repairs, drydockings or special or intermediate surveys.
3) Total voyage days for fleet reflect the total days the vessels we operated were in our possession for the relevant period net of off-hire days associated with major repairs, drydockings or special or intermediate surveys.
4) Fleet utilization is the percentage of time that our vessels were available for revenue generating voyage days, and is determined by dividing voyage days by fleet calendar days for the relevant period.
5) Total charter days for fleet are the number of voyage days the vessels operated on time or bareboat charters for the relevant period.
6) Total spot market charter days for fleet are the number of voyage days the vessels operated on spot market charters for the relevant period.
7) Fleet operational utilization is the percentage of time that our vessels generated revenue and is determined by dividing voyage days excluding idle days by fleet calendar days for the relevant period.

Reconciliation of Adjusted Net Income, EBITDA, adjusted EBITDA and adjusted EPS:

Adjusted net income represents net income before share based compensation. EBITDA represents net income before interest and finance costs, interest income and depreciation. Adjusted EBITDA represents net income before interest and finance costs, interest income, depreciation and share based compensation.

Adjusted EPS represents Adjusted net income divided by the weighted average number of shares. EBITDA, adjusted EBITDA, adjusted net income and adjusted EPS are not recognized measurements under U.S. GAAP. Our calculation of EBITDA, adjusted EBITDA, adjusted net income and adjusted EPS may not be comparable to that reported by other companies in the shipping or other industries. In evaluating Adjusted EBITDA, Adjusted net income and Adjusted EPS, you should be aware that in the future we may incur expenses that are the same as or similar to some of the adjustments in this presentation.

EBITDA, adjusted EBITDA, adjusted net income and adjusted EPS are included herein because they are a basis, upon which we and our investors assess our financial performance. They allow us to present our performance from period to period on a comparable basis and provide investors with a means of better evaluating and understanding our operating performance. Management also uses these non-GAAP financial measures in making financial, operating and planning decisions and in evaluating our performance.

(Expressed in United States Dollars,
except number of shares)
Second Quarter Ended
June 30th,
Six Months Period Ended
June 30th,
  2025 2026 2025 2026
Net Income – Adjusted Net Income        
Net income 12,759,434 34,758,699 24,050,420 62,779,787
Plus share based compensation 671,643 519,451 1,560,719 1,101,156
Adjusted Net Income 13,431,077 35,278,150 25,611,139 63,880,943
         
Net income – EBITDA        
Net income 12,759,434 34,758,699 24,050,420 62,779,787
Plus interest and finance costs 838,089 383,595 1,444,472 592,147
Less interest income (2,274,170) (2,111,496) (4,458,564) (3,921,937)
Plus depreciation 5,746,291 8,194,580 10,749,128 16,125,505
EBITDA 17,069,644 41,225,378 31,785,456 75,575,502
         
Net income – Adjusted EBITDA        
Net income 12,759,434 34,758,699 24,050,420 62,779,787
Plus share based compensation 671,643 519,451 1,560,719 1,101,156
Plus interest and finance costs 838,089 383,595 1,444,472 592,147
Less interest income (2,274,170) (2,111,496) (4,458,564) (3,921,937)
Plus depreciation 5,746,291 8,194,580 10,749,128 16,125,505
Adjusted EBITDA 17,741,287 41,744,829 33,346,175 76,676,658
         
EPS        
Numerator        
Net income 12,759,434 34,758,699 24,050,420 62,779,787
Less: Cumulative dividends on preferred shares (435,246) (435,246) (870,492) (870,492)
Less: Undistributed earnings allocated to non-vested shares (410,718) (517,685) (869,583) (1,041,668)
Net income attributable to common shareholders, basic 11,913,470 33,805,768 22,310,345 60,867,627
Denominator        
Weighted average number of shares 33,267,487 45,350,830 33,107,097 45,338,067
EPS – Basic 0.36 0.75 0.67 1.34
         
Adjusted EPS        
Numerator        
Adjusted net income 13,431,077 35,278,150 25,611,139 63,880,943
Less: Cumulative dividends on preferred shares (435,246) (435,246) (870,492) (870,492)
Less: Undistributed earnings allocated to non-vested shares (433,101) (525,519) (928,132) (1,060,195)
Adjusted net income attributable to common shareholders, basic 12,562,730 34,317,385 23,812,515 61,950,256
         
Denominator        
Weighted average number of shares 33,267,487 45,350,830 33,107,097 45,338,067
Adjusted EPS 0.38 0.76 0.72 1.37

Imperial Petroleum Inc.
Unaudited Consolidated Statements of Income
(Expressed in United States Dollars, except for number of shares)

          Quarters Ended June 30,   Six Month Periods Ended June 30,
          2025   2026   2025   2026
                 
Revenues                    
  Revenues     36,348,819   87,073,466   68,440,445   148,786,861
                       
Expenses/(Income)                    
  Voyage expenses     10,271,965   21,058,763   20,326,079   33,065,678
  Voyage expenses – related party   432,863   1,036,218   834,616   1,785,657
  Vessels’ operating expenses   8,297,520   14,192,655   15,319,448   25,267,523
  Vessels’ operating expenses – related party 109,000   160,000   207,500   335,000
  Drydocking costs     1,692,033   7,525,438   1,692,033   8,959,177
  Management fees – related party     564,960   839,960   1,036,200   1,627,120
  General and administrative expenses   1,064,964   1,097,701   2,282,941   2,152,123
  Depreciation     5,746,291   8,194,580   10,749,128   16,125,505
  Other operating income     —   (430,324)   —   (430,324)
Total expenses, net     28,179,596   53,674,991   52,447,945   88,887,459
                       
Income from operations   8,169,223   33,398,475   15,992,500   59,899,402
                       
Other (expenses)/income                
  Interest and finance costs   (3,115)   (4,471)   (6,722)   (8,618)
  Interest expense – related party   (834,974)   (379,124)   (1,437,750)   (583,529)
  Interest income     2,274,170   2,111,496   4,458,564   3,921,937
  Dividend income from related party     189,583   189,583   377,083   377,083
  Foreign exchange gain/(loss)   2,964,547   (557,260)   4,666,745   (826,488)
Other income, net     4,590,211   1,360,224   8,057,920   2,880,385
                       
Net Income     12,759,434   34,758,699   24,050,420   62,779,787
                       
Earnings per share                  
– Basic       0.36   0.75   0.67   1.34
– Diluted       0.35   0.70   0.65   1.27
                       
Weighted average number of shares              
– Basic       33,267,487   45,350,830   33,107,097   45,338,067
– Diluted       35,172,985   48,126,056   34,407,373   47,874,673
                       


Imperial Petroleum Inc.

Unaudited Consolidated Balance Sheets
(Expressed in United States Dollars)

          December 31,   June 30,
          2025   2026
               
Assets            
Current assets          
  Cash and cash equivalents   5,771,505   7,518,702
  Time deposits     173,282,440   237,712,000
  Trade and other receivables   13,403,555   18,666,099
  Other current assets     1,107,956   1,239,819
  Claims receivable     479,488   909,813
  Inventories     4,720,873   10,422,022
  Advances and prepayments   245,014   671,496
Total current assets     199,010,831   277,139,951
               
Non current assets          
  Operating lease right-of-use asset   —   263,445
  Vessels, net     335,406,781   354,689,276
  Investment in related party   12,990,167   12,983,917
Total non current assets     348,396,948   367,936,638
Total assets       547,407,779   645,076,589
               
Liabilities and Stockholders’ Equity        
Current liabilities          
  Trade accounts payable   5,959,924   13,859,897
  Payable to related parties   3,038,447   35,151,918
  Accrued liabilities     4,195,986   6,373,316
  Operating lease liability, current portion   —   100,985
  Deferred income     3,399,325   2,653,956
Total current liabilities     16,593,682   58,140,072
           
Non current Liabilities          
Operating lease liability, non-current portion     —   162,460
Total non-current liabilities     —   162,460
Total liabilities     16,593,682   58,302,532
               
Commitments and contingencies        
               
Stockholders’ equity          
  Capital stock     489,006   504,406
  Preferred Stock, Series A   7,959   7,959
  Preferred Stock, Series B   160   160
  Treasury stock   (8,390,225)   (19,020,716)
  Additional paid-in capital   344,445,271   349,111,027
  Retained earnings     194,261,926   256,171,221
Total stockholders’ equity     530,814,097   586,774,057
Total liabilities and stockholders’ equity   547,407,779   645,076,589


Imperial Petroleum Inc.

Unaudited Consolidated Statements of Cash Flows
(Expressed in United States Dollars)

          Six Month Periods Ended June 30,
          2025   2026
           
Cash flows from operating activities        
  Net income for the period     24,050,420   62,779,787
               
Adjustments to reconcile net income to net cash      
provided by operating activities:        
  Depreciation     10,749,128   16,125,505
  Non-cash lease expense 38,849   46,941
  Share-based compensation   1,560,719   1,101,156
  Unrealized foreign exchange loss/(gain) on time deposits     (1,030,640)   586,884
               
Changes in operating assets and liabilities:      
  (Increase)/decrease in          
  Trade and other receivables   670,769   (5,262,544)
  Other current assets     485,977   (131,863)
  Claims receivable     —   (430,325)
  Inventories     1,319,526   (5,701,149)
  Changes in operating lease liabilities   (38,849)   (46,941)
  Advances and prepayments   25,021   (426,482)
  Due from related parties   2,084   6,250
  Increase/(decrease) in          
  Trade accounts payable   955,699   7,899,973
  Due to related parties   2,990,748   291,101
  Accrued liabilities     (132,345)   2,177,330
  Deferred income     765,748   (745,369)
Net cash provided by operating activities   42,412,854   78,270,254
               
Cash flows from investing activities        
  Payments for improvement and capitalized expenses of vessels (417,320)   —
  Increase in bank time deposits   (101,608,390)   (331,215,788)
  Maturity of bank time deposits   157,081,011   266,199,344
Net cash provided by/(used in) investing activities   55,055,301   (65,016,444)
               
Cash flows from financing activities        
  Stock repurchases     —   (10,630,491)
  Dividends paid on preferred shares   (868,075)   (876,122)
  Repayment of seller and capital expenditures financing   (36,700,000)   —
Net cash used in financing activities   (37,568,075)   (11,506,613)
               
Net increase in cash and cash equivalents 59,900,080   1,747,197
Cash and cash equivalents at beginning of period 67,783,531   5,771,505
Cash and cash equivalents at end of period 127,683,611   7,518,702
Cash breakdown        
  Cash and cash equivalents   127,683,611   7,518,702
Total cash and cash equivalents shown in the statements of cash flows 127,683,611   7,518,702

Access the segment here

ISELIN, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that Bob Jahr, Chief Executive Officer, recently participated in a Virtual Investor CEO Connect segment discussing the significance of the FDA approval of LYTENAVA and the Company’s plans for its U.S. commercial launch.

During the segment, Mr. Jahr discusses the potential of LYTENAVA to address the significant U.S. retina market by providing physicians with the only FDA-approved ophthalmic formulation of bevacizumab for wet AMD. He also discusses the Company’s potential to shift existing off-label use to LYTENAVA and its opportunity to achieve more than $500 million in annual U.S. sales by 2030.

The segment also highlights Outlook Therapeutics’ commercial readiness efforts ahead of its planned U.S. launch before the end of 2026, including manufacturing, distribution, market access, reimbursement, and physician education, as well as key learnings from the Company’s commercialization efforts in Europe.

“FDA approval of LYTENAVA marks an important transformation for Outlook Therapeutics as we move into our next phase as a commercial-stage company,” said Bob Jahr. “We believe LYTENAVA has the potential to make a meaningful impact for retina physicians and patients while addressing a significant market opportunity. We are focused on executing our U.S. launch strategy and building on the experience gained through our European commercialization efforts.”

The Virtual Investor CEO Connect segment is available to watch here.

About LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma)

LYTENAVA™ is an ophthalmic formulation of bevacizumab produced in the United States for the treatment of wet AMD. In the United States, LYTENAVA (bevacizumab-vikg) is the only ophthalmic formulation approved by the FDA. LYTENAVA (bevacizumab gamma) is also the subject of a centralized Marketing Authorization granted by the European Commission in the EU and Marketing Authorization granted by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for the treatment of wet AMD. In certain European Union Member States, LYTENAVA must receive pricing and reimbursement approval before it can be sold.

Bevacizumab-vikg (bevacizumab gamma in the EU and UK) is a recombinant humanized IgG1 monoclonal antibody specific to human vascular endothelial growth factor (VEGF). Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. LYTENAVA binds to all isoforms of VEGF-A, thereby preventing interaction with receptors VEGFR-1 and VEGFR-2. By inhibiting VEGF-A, LYTENAVA suppresses endothelial cell proliferation, neovascularization, and vascular permeability. Inhibition of such activity targets a pathophysiologic process that contributes to vision loss.

Important Safety Information and Indication

LYTENAVA (bevacizumab-vikg) is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (nAMD).

Contraindications

LYTENAVA is contraindicated in patients with ocular or periocular infections, in patients with active intraocular inflammation, and in patients with a known hypersensitivity to bevacizumab products or any of the ingredients in LYTENAVA. Hypersensitivity reactions may manifest as severe intraocular inflammation.

Warnings and Precautions

Intravitreal injections have been associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering LYTENAVA. In addition, patients should be monitored following the injection to permit early treatment should an infection occur.

Increases in intraocular pressure have been noted post-injection (up to 60 minutes) while being treated with LYTENAVA. Monitor intraocular pressure prior to and following intravitreal injection with LYTENAVA and manage appropriately.

Although there was a low rate of arterial thromboembolic events (ATEs) observed in the LYTENAVA clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).

Adverse Reactions

The most common adverse reaction (≥1%) reported in patients receiving LYTENAVA was conjunctival hemorrhage (4%), eye pain (2%), and vitreous floaters (2%). These are not all the possible side effects of LYTENAVA.

You are encouraged to report side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Outlook Therapeutics at 1-833-999-OTLK (6855).

Please see the full U.S. Prescribing Information for LYTENAVA here.

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of LYTENAVA (bevacizumab-vikg (U.S.), bevacizumab gamma (E.U.)). LYTENAVA is the only ophthalmic formulation of bevacizumab to receive U.S. FDA approval and European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA (bevacizumab gamma) in Germany, Austria, and the UK as a treatment for wet AMD.

Forward-Looking Statements

This press release contains statements that may or are considered “forward-looking statements”. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “could,” “continue,” “expect,” “may,” “on track,” “plan,” “potential,” “target,” “will,” or “would”, the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. These include, among others, express or implied discussions regarding the Company’s planned launch of LYTENAVA in the United States and other jurisdictions and the timing thereof; expectations concerning potential revenue generation from sales of LYTENAVA; expectations surrounding market adoption of LYTENAVA; expectations regarding the potential impact of LYTENAVA in the retina community; Outlook Therapeutics’ development or future revenue plans for LYTENAVA generally; and other statements that are not historical fact. Although Outlook Therapeutics believes that it has a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting Outlook Therapeutics and are subject to risks, uncertainties, and factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond its control. These risk factors include those risks associated with developing and commercializing pharmaceutical product candidates, risks in obtaining necessary regulatory approvals, the content and timing of decisions by regulatory bodies, as well as those risks detailed in Outlook Therapeutics’ filings with the Securities and Exchange Commission (the SEC), including the Current Report on Form 8-K filed with the SEC on August 12, 2026 and the Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and future reports Outlook Therapeutics files with the SEC, which include uncertainty of market conditions and future impacts related to macroeconomic factors, including as a result of the ongoing overseas conflicts, tariffs, and trade tensions, fluctuations in interest rates and inflation, and potential future bank failures on the global business environment. These risks may cause actual results to differ materially from those expressed or implied by forward-looking statements in this press release. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Outlook Therapeutics does not undertake any obligation to update, amend, or clarify these forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities law.

Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
OTLK@jtcir.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.